CR20120261A - Derivados de piridino-piridinonas, su preparación y su aplicación en terapéutica - Google Patents

Derivados de piridino-piridinonas, su preparación y su aplicación en terapéutica

Info

Publication number
CR20120261A
CR20120261A CR20120261A CR20120261A CR20120261A CR 20120261 A CR20120261 A CR 20120261A CR 20120261 A CR20120261 A CR 20120261A CR 20120261 A CR20120261 A CR 20120261A CR 20120261 A CR20120261 A CR 20120261A
Authority
CR
Costa Rica
Prior art keywords
derivatives
piridinonas
piridino
therapeutics
preparation
Prior art date
Application number
CR20120261A
Other languages
English (en)
Inventor
Gilbert Lassalle
Valerie Martin
Gary Mccort
Cecile Volle-Challier
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42133583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120261(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CR20120261A publication Critical patent/CR20120261A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La invención se refiere (i) a derivados de piridino-piridinonas que responden a la formula (i) en la que R1 representa un átomo de hidrógeno o un grupo alquilo (C1-C4).
CR20120261A 2009-11-23 2012-05-21 Derivados de piridino-piridinonas, su preparación y su aplicación en terapéutica CR20120261A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0905602A FR2952934B1 (fr) 2009-11-23 2009-11-23 Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
CR20120261A true CR20120261A (es) 2012-07-04

Family

ID=42133583

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120261A CR20120261A (es) 2009-11-23 2012-05-21 Derivados de piridino-piridinonas, su preparación y su aplicación en terapéutica

Country Status (27)

Country Link
US (1) US8623893B2 (es)
EP (1) EP2504338B1 (es)
JP (1) JP2013511501A (es)
KR (1) KR20120099732A (es)
CN (1) CN102762558A (es)
AR (1) AR079077A1 (es)
AU (1) AU2010320692A1 (es)
BR (1) BR112012012403A2 (es)
CA (1) CA2781935A1 (es)
CL (1) CL2012001322A1 (es)
CO (1) CO6481011A2 (es)
CR (1) CR20120261A (es)
DO (1) DOP2012000136A (es)
EA (1) EA201290383A1 (es)
EC (1) ECSP12011916A (es)
FR (1) FR2952934B1 (es)
GT (1) GT201200154A (es)
IL (1) IL219888A0 (es)
MA (1) MA33819B1 (es)
MX (1) MX2012005988A (es)
NI (1) NI201200095A (es)
NZ (1) NZ600108A (es)
PE (1) PE20121338A1 (es)
TN (1) TN2012000229A1 (es)
TW (1) TWI476197B (es)
UY (1) UY33049A (es)
WO (1) WO2011061458A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
SI2874625T1 (sl) * 2012-07-17 2017-10-30 Sanofi Uporaba inhibitorjev VEGFR-3 za zdravljenje hepatoceličnega karcinoma
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CA3037369A1 (en) 2016-09-18 2018-03-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Yap1 inhibitors that target the interaction of yap1 with oct4
EP3706740A4 (en) * 2017-11-06 2021-07-28 Suzhou Pengxu Pharmatech Co., Ltd. METHOD FOR MANUFACTURING ACALABRUTINIB
JP7319977B2 (ja) * 2017-12-06 2023-08-02 リン バイオサイエンス，インコーポレイテッド チューブリン阻害剤
PE20211450A1 (es) 2018-03-14 2021-08-05 H Lee Moffitt Cancer Ct & Res Inhibidores de yap1 que dirigen la interaccion de yap1 con oct4

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4323574B2 (ja) * 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤
US5994367A (en) * 1997-03-07 1999-11-30 The University Of North Carolina At Chapel Hill Method for treating tumors using 2-aryl-naphthyridin-4-ones
JP3739916B2 (ja) * 1997-12-02 2006-01-25 第一製薬株式会社 サイトカイン産生阻害剤
ES2247325T3 (es) * 2001-05-24 2006-03-01 MERCK FROSST CANADA & CO. Inhibidores de 1-biaril-1,8-naftiridin-4-ona fosfodiesterasa-4.
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
AU2003290699B2 (en) * 2002-11-13 2009-08-27 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
GB0321621D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
US20080234263A1 (en) 2003-09-16 2008-09-25 Laurent Francois Andre Hennequin Quinazoline Derivatives
WO2005091857A2 (en) * 2004-03-12 2005-10-06 Bayer Pharmaceuticals Corporation 1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders
WO2007113565A1 (en) * 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
WO2007113548A1 (en) * 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives
CA2666116A1 (en) * 2006-10-16 2008-04-24 Novartis Ag Phenylacetamides useful as protein kinase inhibitors
EP2139888A2 (en) * 2007-03-28 2010-01-06 Array Biopharma, Inc. Imidazoý1,2-a¨pyridine compounds as receptor tyrosine kinase inhibitors
FR2917412B1 (fr) 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2917413B1 (fr) 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2954943B1 (fr) 2010-01-07 2013-03-01 Sanofi Aventis Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors

Also Published As

Publication number Publication date
IL219888A0 (en) 2012-07-31
WO2011061458A1 (fr) 2011-05-26
CL2012001322A1 (es) 2012-08-17
FR2952934A1 (fr) 2011-05-27
PE20121338A1 (es) 2012-10-15
FR2952934B1 (fr) 2012-06-22
ECSP12011916A (es) 2012-07-31
AR079077A1 (es) 2011-12-21
US20130005724A1 (en) 2013-01-03
US8623893B2 (en) 2014-01-07
MX2012005988A (es) 2012-09-07
KR20120099732A (ko) 2012-09-11
CO6481011A2 (es) 2012-07-16
TWI476197B (zh) 2015-03-11
UY33049A (es) 2011-06-30
AU2010320692A1 (en) 2012-06-14
JP2013511501A (ja) 2013-04-04
DOP2012000136A (es) 2012-08-15
TW201121971A (en) 2011-07-01
BR112012012403A2 (pt) 2017-10-10
TN2012000229A1 (fr) 2013-12-12
EP2504338B1 (fr) 2015-03-18
MA33819B1 (fr) 2012-12-03
EP2504338A1 (fr) 2012-10-03
CN102762558A (zh) 2012-10-31
NI201200095A (es) 2012-08-20
EA201290383A1 (ru) 2013-01-30
NZ600108A (en) 2013-06-28
GT201200154A (es) 2013-11-07
CA2781935A1 (fr) 2011-05-26

Similar Documents

Publication Publication Date Title
CR20120261A (es) Derivados de piridino-piridinonas, su preparación y su aplicación en terapéutica
CR20130001A (es) Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
CR11596A (es) Derivados de urea de tetrahidroquinoxalina, su preparacion y su aplicacion en terapeutica
DOP2011000245A (es) Derivados de tiadiazoles y oxadiazoles, su preparacion y su aplicacion en terapeutica
NI201100011A (es) Derivados de piridino - piridinonas, su preparación y su aplicación en terapéutica.
EA201171246A1 (ru) Содержащая трегалулозу композиция, ее получение и применение
ECSP099791A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparación y su aplicación en terapéutica
UY32517A (es) Derivados de nicotinamida, su preparación y su aplicación en terapéutica
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
IN2012DN00695A (es)
MX356126B (es) Uso de estabilizadores de glutamina.
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
ECSP12011569A (es) Derivados de pirazoles, su preparación y su aplicación terapéutica
CR9565A (es) Derivados del 4,5-diarilpirrol, su preparacion y su aplicacion en terapeutica
HN2012001262A (es) Nuevos derivados de 8heterociclo-piperidina condensada)-( piperazinil)-1-alcanona o de (heterociclo-pirrolidina condensada)-(piperazinil)-1-alcanona y su utilizacion como inhibidores de p75
CO6300943A2 (es) Derivados de 2-oxo-aquil-1-piperazin-2-ona su preparacion y su aplicacion en terapeutica
UY34869A (es) Derivados de pirimidinonas, su preparación y su aplicación en terapéutica.
CR10969A (es) Derivados de azabicicloalcano, su preparacion y su aplicacion en terapeutica
CO6501125A2 (es) Nuevos derivados (heterociclico-tetrahidro-piridin)-(piperazinil)-1- alcanona y (heterociclo-dhidro-pirrolidin)-(piperazinil)-1-alcanona y su utilización como inhibidores de p75
UY33574A (es) Nuevos derivados dihidrobenzoxatiazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CR20110306A (es) Derivados de morfina-6-glucuronido, su preparación y su aplicación en terapéutica
NI201200039A (es) Nuevos derivados dihidro - oxazolobenzodiazepinonas, su procedi
UY32515A (es) Nuevos derivados anticancerosos de nicotinamida, su preparación y su aplicación terapéutica
MA33932B1 (fr) Dérivés de 2-aldoximino-5-fluoropyrimidine